Previous 10 | Next 10 |
Notes from today's conference call at CytoDyn ( OTCQB:CYDY ) regarding the results from a Phase 2 clinical trial evaluating leronlimab in COVID-19 patients with mild-to-moderate symptoms. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
Equillium stock jumps on encouraging Itolizumab interim data Equillium Inc. ( EQ ) reported positive interim data for its lead drug candidate Itolizumab from the first two cohorts of the Phase 1b trial. The drug candidate was found to be generally well-tolerated and five out of seven pat...
VANCOUVER, Washington, Aug. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...
CytoDyn ( OTCQB:CYDY -1.9% ) reports , what it says, are "clinically significant" results from its Phase 2 clinical trial evaluating leronlimab in COVID-19 patients with mild-to-moderate symptoms. More news on: CytoDyn Inc., Healthcare stocks news, Stocks on the move, Read more .....
Relief Therapeutics Holdings AG ( RLFTF ) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading under .10 per share. It was the rediscovery of the properties of their drug RLF-100, a propr...
Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab Leronlimab also demonstrated statistically significant improvement versus placebo in key secondary efficacy endpoint, National Early Warning Score 2 scale (NEWS2) Results w...
Adam Smith (1723-1790) was not who you think he was. I'm talking about the original Adam Smith who wrote The Wealth of Nations (1776) and spent most of his life in Edinburgh, Scotland. The more recent "Adam Smith" - nom de plume of the late George Goodman who wrote The Money Game (1967) - ...
• BLA-type submission planned this month in U.K. for HIV combination therapy with 350 mg weekly dose • COVID-19 Phase 2 topline report to be submitted for consideration of emergency approval of leronlimab for patients with mild-to-moderate symptoms to U.K. and other co...
Amarin reports better than expected financial numbers for second quarter Amarin Corporation plc (AMRN) announced its second quarter results, and the numbers were better than anticipated. The company also provided updates about its business operations. Amarin is looking to increase the po...
VANCOUVER, Washington, Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company, announced today an independent Data Safety Monitoring Committee (“DSMC”) completed its first safety re...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...